Fenretinide Improves Intestinal Barrier Function and Mitigates Alcohol Liver Disease

Area of Science:

• Hepatology and Gastroenterology
• Pharmacology
• Immunology

Background:

• Alcohol liver disease (ALD) is a leading cause of liver mortality with limited therapeutic options.
• ALD pathogenesis involves intestinal barrier dysfunction, endotoxin translocation, and TLR4-mediated hepatic inflammation.
• Fenretinide (Fen) is a synthetic retinoid with anti-inflammatory and anti-cancer properties.

Purpose of the Study:

• To investigate Fenretinide's (Fen) efficacy in ameliorating alcohol liver disease (ALD) hallmarks.
• To assess Fen's impact on intestinal permeability and TLR4-mediated inflammation in a mouse model of chronic ethanol (EtOH) exposure.

Main Methods:

• A mouse model of chronic ethanol (EtOH) exposure was utilized.
• Intestinal permeability, tight junction protein expression (claudin-1, occludin), endotoxemia, and hepatic steatosis were assessed.
• Hepatic and intestinal expression of TNF-α and TLR4-positive cells (macrophages, Kupffer cells, hepatocytes) were analyzed.

Main Results:

• EtOH exposure increased intestinal permeability, reduced tight junction proteins, and elevated endotoxemia and hepatic steatosis.
• Fen treatment prevented EtOH-induced intestinal barrier dysfunction and endotoxemia.
• Fen significantly reduced hepatic steatosis, liver injury, and expression of TNF-α and TLR4-positive cells in EtOH-exposed mice.

Conclusions:

• Fenretinide (Fen) demonstrates significant therapeutic potential against alcohol liver disease (ALD).
• Fen may exert its protective effects by restoring intestinal barrier integrity and suppressing TLR4-driven inflammation.
• Further pre-clinical studies are warranted to explore Fen as a novel anti-ALD therapeutic agent.